Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.

Drug metabolism and disposition: the biological fate of chemicals - 1 Sept 2010

Oishi Masayo, Chiba Koji, Malhotra Bimal, Suwa Toshio

Abstract excerpt

This study was conducted to investigate the effect of the reduced function allele CYP2D6*10, which can be the cause of an intermediate metabolizer (IM), on tolterodine pharmacokinetics. Tolterodine is mainly metabolized to an active 5-hydroxymethyl metabolite (5-HM) by CYP2D6, and 5-HM is also metabolized by CYP2D6. Asian and white healthy volunteers (n = 108) received once daily multiple doses of tolterodine,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genotype
Share to Benzhydryl Compounds
Share to Case-Control Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chromatography, High Pressure Liquid

Share to Cresols

Share to Cytochrome P-450 CYP2D6

Share to Muscarinic Antagonists

Source

Identifiers

PMID: 20530222
DOI: 10.1124/dmd.110.033407

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of the CYP2D6*10 genotype on tolterodine pharmacokinetics.PMID 20530222Read ↗

Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences.Semantic proximity Read ↗

Effects of the CYP2D6*10 allele on the pharmacokinetics of atomoxetine and its metabolites.Semantic proximity Read ↗

Influence of CYP2D6*10 on the pharmacokinetics of metoprolol in healthy Korean volunteers.Semantic proximity Read ↗

Influence of CYP2D6 and CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy volunteers.Semantic proximity Read ↗

Effect of 22 CYP2D6 variants found in the Chinese population on tolterodine metabolism in vitro.Semantic proximity Read ↗

Pharmacokinetics, safety, and tolerability of atomoxetine and effect of CYP2D6*10/*10 genotype in healthy Japanese men.Semantic proximity Read ↗

Effects of CYP2D6*10 allele on the pharmacokinetics of tolperisone.Semantic proximity Read ↗

Study on genotype and phenotype of novel CYP2D6 variants using pharmacokinetic and pharmacodynamic models with metoprolol as a substrate drug.Semantic proximity Read ↗

Effects of CYP2C19 genetic polymorphism on the pharmacokinetics of tolperisone in healthy subjects.Semantic proximity Read ↗

CYP2D6 allele frequencies in Korean population, comparison with East Asian, Caucasian and African populations, and the comparison of metabolic activity of CYP2D6 genotypes.Semantic proximity Read ↗

Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.Semantic proximity Read ↗

Tamsulosin exposure is significantly increased by the CYP2D6*10/*10 genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.